Antidepressant-like effects of paeoniflorin on post-stroke depression in a rat model

Neurological Research

Volumn 41, Issue 5, 2019, Pages 446-455

  Hu, Ming zhe ^a   Wang, An rong ^b   Zhao, Ze yu ^c   Chen, Xiang yan ^d   Li, Yan bin ^e   Liu, Bin ^e  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c WEIFANG MEDICAL UNIVERSITY   (China)

^d Zibo City Hospital of Traditional Chinese Medicine   (China)

^e SHANDONG UNIVERSITY   (China)

Author keywords

BDNF; fluoxetine; p CREB; paeoniflorin; Post stroke depression

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; PAEONIFLORIN; SUCROSE; ANTIDEPRESSANT AGENT; BDNF PROTEIN, RAT; CREB1 PROTEIN, RAT; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCOSIDE; TERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; GENE EXPRESSION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; IMMUNOFLUORESCENCE; MALE; MOTOR COORDINATION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OPEN FIELD TEST; POST-STROKE DEPRESSION; RAT; STIMULUS; STRESS; SUCROSE PREFERENCE TEST; WESTERN BLOTTING; ANIMAL; CEREBROVASCULAR ACCIDENT; COMPLICATION; DISEASE MODEL; DRUG EFFECT; MENTAL STRESS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CA1 REGION, HIPPOCAMPAL; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; FLUOXETINE; GLUCOSIDES; MALE; MONOTERPENES; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; STRESS, PSYCHOLOGICAL; STROKE;

EID: 85061588044     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1080/01616412.2019.1576361     Document Type: Article

References (34)

1. Paolucci S, Antonucci G, Pratesi L, et al. Poststroke depression and its role in rehabilitation of inpatients. Arch Phys Med Rehabil. 1999;80:985–990.
2. Arwert HJ, Meesters JJL, Boiten J, et al. Poststroke Depression. Am J Phys Med Rehabil. 2018;97:565–571.
3. Dafer RM, Rao M, Shareef A, et al. Poststroke Depression. Top Stroke Rehabil. 2015;15:13–21.
4. Loubinoux I, Kronenberg G, Endres M, et al. Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med. 2012;16:1961–1969.
5. J. D.P ost stroke depression. The sequelae of cerebral stroke. Neurosci Biobehav Rev. 2018;90:104–114.
6. Arnone D, McKie S, Elliott R, et al. State-dependent changes in hippocampal grey matter in depression.Mol. Psychiatry. 2013;18:1265–1272.
7. Khan S, Ryali V, Bhat P, et al. The hippocampus and executive functions in depression. Ind Psychiatry J. 2015;24:18.
8. Campbell S, MacQueen G., The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004;29:417–426.
9. Ishrat T, Pillai B, Soliman S, et al. Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. Mol Neurobiol. 2015;51:1542–1553.
10. Duman R., Synaptic plasticity and mood disorders. Mol Psychiatry. 2002;7:S29-S34.
11. Ifergane G, Boyko M, Frank D, et al. Biologicaland behavioral patterns of post-stroke depression in rats. Can J Neurol Sci. 2018;45:451–461.
12. Díaz-Ruiz C, Parlato R, Aguado F, et al. Regulation of neural migration by the CREB/CREM transcription factors and altered Dab1 levels in CREB/CREM mutants. Mol Cell Neurosci. 2008;39:519–528.
13. Rasmusson AM, Shi L, Duman R. Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock. Neuropsychopharmacology. 2002;27:133–142.
14. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.
15. Zhao A, Qiu W, Mao L, et al. The efficacy and safety of Jiedu Tongluo granules for treating post-stroke depression with qi deficiency and blood stasis syndrome: study protocol for a randomized controlled trial. Trials. 2018;19.
16. Du Y, Liang H, Zhang L, et al. Administration of Huperzine A exerts antidepressant-like activity in a rat model of post-stroke depression. Pharmacol Biochem Behav. 2017;158:32–38.
17. Sun Y, Xu X, Zhang J, et al. Treatment of depression with Chai Hu Shu Gan San: a systematic review and meta-analysis of 42 randomized controlled trials. BMC Complement Altern Med. 2018;18:66.
18. Mao Q, Zhong X, Qiu F, et al. Protective effects of paeoniflorin against corticosterone-induced neurotoxicity in PC12 cells. Phytother Res. 2012;26:969–973.
19. Xiao L, Wang YZ, Liu J, et al. Effects of paeoniflorin on the cerebral infarction, behavioral and cognitive impairments at the chronic stage of transient middle cerebral artery occlusion in rats. Life Sci. 2005;78:413–420.
20. Li J, Huang S, Huang W, et al. Paeoniflorin ameliorates interferon-alpha-induced neuroinflammation and depressive-like behaviors in mice. Oncotarget. 2017;8:8264.
21. Willner P, Towell A, Sampson D, et al. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl). 1987;93:358–364.
22. Sasaki M, Honmou O, Kocsis JD. A rat middle cerebral artery occlusion model and intravenous cellular delivery. Methods Mol Biol. 2009;549:187–195.
23. Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91.
24. Goldstein LB, and Davis JN. Beam-walking in rats: studies towards developing an animal model of functional recovery after brain injury. J Neurosci Methods. 1990;31:101–107.
25. Li S, Wang C, Wang M, et al. Tang Y:antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms. Life Sci. 2007;80:1373–1381.
26. Zurita A, Martijena I, Cuadra G, et al. Early exposure to chronic variable stress facilitates the occurrence of anhedonia and enhanced emotional reactions to novel stressors: reversal by naltrexone pretreatment. Behav Brain Res. 2000;117:163–171.
27. Stanford SC. The open field test: reinventing the wheel. J Psychopharmacol. 2016;21:134–135.
28. Pan SJ, Tan YL, Yao SW, et al. Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression. Acta Pharmacol Sin. 2018;39:1463–1472.
29. Lu Y, Ho CS, McIntyre RS, et al. Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. Brain Res Bull. 2018;142:1–7.
30. Sun H, Li Q, Liu Y, et al. Xiao-Yao-San, a Chinese medicine formula, ameliorates chronic unpredictable mild stress induced polycystic ovary in rat. Front Physiol. 2017;8.
31. Zhong S, Ge Q, Li Q, et al. Peoniflorin attentuates Aβ(1–42)-mediated neurotoxicity by regulating calcium homeostasis and ameliorating oxidative stress in hippocampus of rats. J Neurol Sci. 2009;280:71–78.
32. Qiu F, Zhong X, Mao Q, et al. The antidepressant-like effects of paeoniflorin in mouse models. Exp Ther Med. 2013;5:1113–1116.
33. Sasaki K, Yoshizaki F. Investigation into hippocampal nerve cell damage through the mineralocorticoid receptor in mice. Mol Med Rep. 2015;12:7211–7220.
34. Orlovsky MA, Dosenko VE, Spiga F, et al. Hippocampus remodeling by chronic stress accompanied by GR, proteasome and caspase-3 overexpression. Brain Res. 2014;1593:83–94.